Overview

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Status:
Not yet recruiting
Trial end date:
2023-07-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 has an adequate clinical profile to warrant further clinical development in this indication.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals